The American Cancer Society estimates approximately 79,320 new non-Hodgkin's lymphoma cases and 19,970 related deaths in the United States in 2026, with overall 5-year relative survival near 74%, ranging from about 88% at stage I to 64% at stage IV. More than half of all diagnoses occur in adults 65 and older, and age-adjusted incidence in those 75-84 reaches roughly 110.9 per 100,000, nearly six times the rate in the general population. Because NHL comprises more than 60 biologically distinct subtypes with sharply different treatment algorithms and prognoses, precise histologic and staging documentation is essential to appropriate risk adjustment and care coordination.
AAVBC's Non-Hodgkin's Lymphoma Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 coding specificity across NHL subtypes (C82-C88), HCC/RAF mapping, Lugano staging and Deauville response assessment, subtype-specific prognostic indices (IPI, FLIPI, MIPI), differentiation from Hodgkin lymphoma, MEAT documentation standards, and NCCN-aligned treatment and survivorship management. Grounded in NCCN and current oncology guidance, this guide supports consistent, individualized clinical decision-making, helping care teams recognize red-flag presentations early, code subtype and stage with precision, and coordinate care with hematology, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of Non-Hodgkin's lymphoma — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
The American Cancer Society estimates approximately 79,320 new non-Hodgkin's lymphoma cases and 19,970 related deaths in the United States in 2026, with overall 5-year relative survival near 74%, ranging from about 88% at stage I to 64% at stage IV. More than half of all diagnoses occur in adults 65 and older, and age-adjusted incidence in those 75-84 reaches roughly 110.9 per 100,000, nearly six times the rate in the general population. Because NHL comprises more than 60 biologically distinct subtypes with sharply different treatment algorithms and prognoses, precise histologic and staging documentation is essential to appropriate risk adjustment and care coordination.
AAVBC's Non-Hodgkin's Lymphoma Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 coding specificity across NHL subtypes (C82-C88), HCC/RAF mapping, Lugano staging and Deauville response assessment, subtype-specific prognostic indices (IPI, FLIPI, MIPI), differentiation from Hodgkin lymphoma, MEAT documentation standards, and NCCN-aligned treatment and survivorship management. Grounded in NCCN and current oncology guidance, this guide supports consistent, individualized clinical decision-making, helping care teams recognize red-flag presentations early, code subtype and stage with precision, and coordinate care with hematology, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of Non-Hodgkin's lymphoma — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
